Choose Impact Over Ambition | Novonesis CEO Ester Baiget

Why It Matters

The shift positions Novonesis at the forefront of sustainable biotech, unlocking growth through integrated biosolutions and cross‑border M&A, and signals a broader industry trend where purpose‑led leadership drives strategic realignment.

Key Takeaways

• Baiget left Dow after 25 years to lead Novozymes' biosolutions push
• Novozymes rebranded from enzyme maker to biosolutions company
• Strategic shift enabled merger with Danish biotech Chr. Hansen
• Baiget cites purpose, curiosity, and strong team as leadership pillars
• CEO role less lonely when building collaborative, high‑performing teams

Pulse Analysis

Ester Baiget’s decision to leave Dow after a quarter‑century and take the helm at Novozymes—now operating as Novonesis—reflects a growing wave of purpose‑driven leadership in the biotech sector. Executives are increasingly prioritising societal impact and scientific potential over traditional career milestones, a mindset that resonates with investors seeking ESG‑aligned growth. Baiget’s narrative, shared on CNBC’s Executive Decisions podcast, underscores how personal values and curiosity can outweigh the lure of a prestigious title, setting a tone for the company’s next chapter. Under Baiget’s guidance, Novozymes has rebranded itself from a niche enzyme supplier to a comprehensive biosolutions platform.

This repositioning broadens the addressable market, allowing the firm to tackle challenges in agriculture, health and industrial sustainability with a unified portfolio of biologics. The strategic realignment was a prerequisite for the high‑profile merger with Danish biotech Chr. Hansen, creating one of Europe’s largest bio‑ingredients powerhouses. Analysts view the deal as a catalyst for scale, cross‑selling opportunities and accelerated R&D pipelines.

Baiget also emphasizes that the CEO role is less solitary when surrounded by a collaborative, high‑performing team. By fostering a culture where curiosity is rewarded and setbacks are kept in perspective, she aims to translate scientific ambition into commercial impact. For stakeholders, this approach promises faster innovation cycles, stronger talent retention, and a clearer pathway to delivering measurable environmental benefits. As the biosolutions market expands, Novonesis’ purpose‑first strategy could become a benchmark for biotech firms navigating rapid consolidation and heightened sustainability expectations.

Original Description

After 25 years at Dow, Ester Baiget left a business she loved to take on the top job at Novozymes — now Novonesis. It was not a move driven by ego, or a lifelong plan to become CEO. Baiget says she did not need the title. What drew her in was purpose, potential and a belief that she could help the company make a bigger impact through biology.

In this episode of “Executive Decisions,” the Novonesis CEO reflects on the family values that shaped her, the teacher who nudged her toward chemical engineering and the mother who pushed her to attend the interview that began her 25-year career at Dow.

Baiget discusses why curiosity has guided her more than career planning, how she learned not to take setbacks out of proportion and why the CEO role is less lonely than many assume when you build the right team.

She also explains the strategic shift that led Novozymes to see itself not as an enzyme company, but as a biosolutions company — a decision that helped make the merger with Danish biotech company Chr. Hansen possible.

Subscribe to "Executive Decisions with Steve Sedgwick" wherever you get your podcasts.

#CNBC #CNBCPodcast #ExecutiveDecisions

-----

Subscribe: @cnbci

CNBC International Live: @cnbcinternationalive

LinkedIn: https://www.linkedin.com/showcase/cnbc/

TikTok: https://www.tiktok.com/@cnbc

Facebook: https://www.facebook.com/cnbc

Instagram: https://www.instagram.com/cnbc

Threads: https://www.threads.net/@cnbc

X: https://twitter.com/CNBC

Telegram: https://t.me/cnbc